J. Bennouna

发表

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

K. Emancipator, P. Ott, E. Chan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

T. Conroy, P. Laurent-Puig, M. Ychou, 2014, British Journal of Cancer.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Pierre Michel, Olivier Bouché, Jaafar Bennouna, 2011, The New England journal of medicine.

FREQUENT HOMOZYGOUS DELETIONS OF TYPE I INTERFERON GENES IN PLEURAL MESOTHELIOMA CONFER SENSITIVITY TO ONCOLYTIC MEASLES VIRUS.

S. Minvielle, F. Tangy, A. Magnan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.

Manish R. Patel, J. Nemunaitis, A. Heydebreck, 2016 .

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, The Lancet. Oncology.

Impact of Air Gap on Intensity-Modulated Proton Therapy Breast Plans.

S. Rana, J. Bennouna, 2019, Journal of medical imaging and radiation sciences.

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

H. Hurwitz, J. Yi, N. Moore, 2011, British Journal of Cancer.

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.

L. Thiberville, P. Souquet, P. Fournel, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma

C. Blanquart, M. Grégoire, S. Deshayes, 2020, Journal for immunotherapy of cancer.

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy

J. Bennouna, J. Fonteneau, Tiphaine Delaunay, 2021, Frontiers in Oncology.

Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.

F. Tangy, S. Caruso, C. Blanquart, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

D. Carbone, E. Felip, T. John, 2021, ESMO open.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.

R. Govindan, P. Postmus, A. Ardizzoni, 2020, Future oncology.

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

C. Redfern, K. Kelly, C. Verschraegen, 2020, Journal for ImmunoTherapy of Cancer.

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

R. Govindan, P. Postmus, A. Ardizzoni, 2021, Frontiers in Oncology.

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

S. Kubicka, U. Siebert, S. Walzer, 2014, Journal of medical economics.

Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028.

S. Jalal, S. Piha-Paul, M. Koshiji, 2015 .

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

M. Denis, J. Bennouna, 2020, Cancer management and research.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

N. Girard, O. Molinier, M. Denis, 2019, Clinical lung cancer.

Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

S. Jalal, S. Piha-Paul, M. Koshiji, 2016 .

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine

M. Denis, J. Bennouna, Y. Touchefeu, 2021, Expert opinion on biological therapy.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

M. Ychou, J. Douillard, F. Goldwasser, 2012, Clinical colorectal cancer.

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

H. Staines, O. Bouché, J. Capdevila, 2011 .

Anticorps anti-EGFR

J. Bennouna, H. Sénellart, 2008 .

Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer

J. Douillard, B. Buecher, M. Mahé, 2006 .

Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy

J. Douillard, J. Bennouna, 2003, Expert review of anticancer therapy.

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.

M. Ducreux, P. Rougier, J. Bennouna, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for colon cancer: a confusing area!

J. Douillard, J. Bennouna, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2011, International journal of cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2009, British Journal of Cancer.

Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer

J. Botbyl, A. Suttle, R. Ruiz-Soto, 2015, Investigational New Drugs.

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

J. Douillard, G. Milano, M. Etienne-Grimaldi, 2012, British journal of clinical pharmacology.

Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?

J. Douillard, J. Bennouna, H. Sénellart, 2008, Clinical colorectal cancer.

Update on European adjuvant trials with irinotecan for colorectal cancer.

J. Douillard, J. Bennouna, V. Barbarot, 2002, Oncology.

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

T. Conroy, M. Ychou, M. Ducreux, 2011, Oncology.

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

A. Carrato, E. Van Cutsem, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

C. Gridelli, K. Syrigos, Y. Ohe, 2018, JAMA oncology.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Clinical Pharmacokinetic Analysis of Tegafur-Uracil (UFT) Plus Leucovorin Given in a New Twice-Daily Oral Administration Schedule

J. Douillard, G. Milano, J. Cardot, 2007, Clinical pharmacokinetics.

Prognostic factors of Colorectal Cancer patients with Brain Metastases.

A. Lièvre, D. Tougeron, J. Bennouna, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors

M. Ducreux, E. Baudin, R. Guimbaud, 2021, Neuroendocrinology.

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

J. Bennouna, E. Frampas, T. Goronflot, 2021, Cancer Immunology, Immunotherapy.

MAGE-A3 et cancer bronchique

S. Hiret, J. Bennouna, H. Senellart, 2010 .

[Molecular biology of lung cancer series].

S. Hiret, J. Bennouna, H. Sénellart, 2010, Revue des maladies respiratoires.

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature

M. Denis, C. Blanquart, J. Bennouna, 2022, Current oncology.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

G. Salles, D. Berton‐Rigaud, J. Rey, 2018, Oncotarget.

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

J. Mazières, I. Rouquette, T. Filleron, 2016, Clinical lung cancer.

Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemonaive Patients

E. Lemarié, C. Tournoux-Facon, J. Pouget, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

O. Molinier, P. Dumont, W. Hilgers, 2018, ESMO Open.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

F. Bonnetain, C. Chouaid, J. Bennouna, 2017, Oncology.

DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.

J. von Pawel, M. Reck, V. Gorbounova, 2014, Lung cancer.

Small Cell Carcinoma of the Esophagus: Analysis of 10 Cases and Review of the Published Data

J. Douillard, J. Bennouna, É. Bardet, 2000, American journal of clinical oncology.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants].

J. Bennouna, H. Sénellart, 2008, Revue des maladies respiratoires.

Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative 18F-FDG PET/CT: Don’t Forget the Thyroid!

E. Mirallié, J. Bennouna, C. Ansquer, 2021, Current oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

R. Kaiser, S. Novello, M. Krzakowski, 2017, Targeted Oncology.

Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers

G. de Pouvourville, D. Moro-Sibilot, C. Chouaid, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

J. Riess, E. Felip, L. Paz-Ares, 2019, Clinical lung cancer.

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2020 .

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

J. Mazières, C. Mascaux, G. Zalcman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

N. Girard, J. Mazières, G. Zalcman, 2020, Respiratory Medicine and Research.

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

M. Shah, P. Enzinger, Xiaolong Fu, 2021, Future oncology.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.

M. Johnstone, E. Mirallié, A. Hamy, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

J. Soria, V. Papadimitrakopoulou, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression

C. Volteau, A. Jarry, J. Mosnier, 2019, Modern Pathology.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

J. Lunceford, T. Mcclanahan, M. Ayers, 2016 .

[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].

A. Jarry, N. Gervois, C. Bossard, 2018, Bulletin du cancer.

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

T. Conroy, G. Deplanque, C. Borg, 2016 .

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

Melissa L. Johnson, B. Besse, P. Garrido, 2020, Lung cancer.

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

T. Matysiak-Budnik, D. Tougeron, J. Bennouna, 2017, British Journal of Cancer.

Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells1

M. Bonneville, J. Mosnier, A. Moreau-Aubry, 2005, The Journal of Immunology.

V gamma 9V delta 2 T cell response to colon carcinoma cells.

M. Bonneville, J. Mosnier, A. Moreau-Aubry, 2005, Journal of immunology.

L. Sequist, K. O'Byrne, T. Mok, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

J. Pignon, T. Conroy, M. Ducreux, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testing

A. Kent, N. Malats, G. Ciliberto, 2020 .

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.

B. Chauffert, C. Lepage, P. Maingon, 2014, European journal of cancer.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

K. Emancipator, P. Ott, E. Chan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.

R. Greil, S. Kubicka, T. Mueller, 2013 .

Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147)

O. Bouché, D. Arnold, T. André, 2012 .

Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with Bev-Based Therapy: Overall Survival Subgroup Findings from ML18147

R. Greil, S. Kubicka, C. Borg, 2012 .

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

6610 POSTER Safety of bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anti-coagulation (FDAC) treated on protocol BO17704

H. Kuo, G. Chang, N. Leighl, 2007 .

Safety of Bevacizumab Treatment in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Full-Dose Anticoagulation (FDAC) Treated on Protocol BO17704

H. Kuo, G. Chang, N. Leighl, 2007 .

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

A. Nicolas, S. Roman-Roman, I. Ray-Coquard, 2021, Biology.

CMAR_A_218751 12593..12602

M. Denis, J. Bennouna, 2020 .

Vinflunine: A New Microtubule Inhibitor Agent

M. Campone, L. Nguyen, J. Delord, 2008, Clinical Cancer Research.

Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer.

C. Bossard, J. Bennouna, E. Cauchin, 2020, Clinical colorectal cancer.

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).

J. Tabernero, F. Ciardiello, M. Valladares-Ayerbes, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

C. Borel, V. Boige, O. Bouché, 2016 .

A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

J. Soria, S. Dimitrijević, H. Burris, 2008 .

Investigating the utilization of beam-specific apertures for the intensity-modulated proton therapy (IMPT) head and neck cancer plans.

S. Rana, M. Storey, J. Bennouna, 2020, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

K. Kelly, H. Safran, D. Spigel, 2022, Future oncology.

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

T. Conroy, M. Ychou, M. Ducreux, 2005 .

Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

J. Douillard, J. Bennouna, P. Thomaré, 2000, Cancer Immunology, Immunotherapy.

Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2013 .

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.

J. Bennouna, 2017, Future oncology.

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer.

M. Shah, P. Enzinger, Y. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

M. Moore, W. Vervenne, C. Verslype, 2008 .

Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses.

A. Hildesheim, T. Whiteside, W. Gooding, 2002, Journal of immunological methods.

Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.

E. Van Cutsem, W. Vervenne, C. Verslype, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy

A. Sandler, M. Reck, J. Bennouna, 2008 .

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

L. Paz-Ares, I. Aronchik, M. Provencio, 2021 .

Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

J. Soria, V. Papadimitrakopoulou, A. Jappe, 2010 .

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

B. Milleron, O. Molinier, S. Laporte, 2011, The Lancet.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

M. Rimbert, I. Philip, E. Bompas, 2008, Cancer Immunology, Immunotherapy.

84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)

J. Lunceford, M. Ayers, H. Rugo, 2017 .

C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells

M. Lotze, P. Hershberger, Candace S. Johnson, 2003, The Prostate.

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

A. Kent, N. Malats, G. Ciliberto, 2020, Biomedicine Hub.

Vinflunine: a novel antitubulin agent in solid malignancies

M. Campone, J. Delord, J. Bennouna, 2005, Expert opinion on investigational drugs.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

R. Ramlau, M. Krzakowski, J. Jassem, 2014, Clinical lung cancer.

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

A. DeMichele, B. Melichar, P. Zatloukal, 2015, The Lancet. Oncology.

Pembrolizumab for the treatment of colorectal cancer

C. Bossard, J. Bennouna, Y. Touchefeu, 2020, Expert opinion on biological therapy.

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

M. Shah, P. Enzinger, B. Cho, 2019, Future oncology.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

J. Lunceford, M. Ayers, H. Rugo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status

C. Volteau, M. Denis, A. Jarry, 2019, Oncoimmunology.

Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib

F. Vallette, D. Decaudin, A. Savina, 2017, Molecular Cancer Therapeutics.

Protective role of Bcl2 in metabolic oxidative stress-induced cell death.

M. Suntharalingam, Y. Lee, J. Rhee, 2001, Journal of cell science.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

J. Schellens, J. Beijnen, M. Campone, 2007, Cancer Chemotherapy and Pharmacology.

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

J. Pignon, M. Ychou, M. Ducreux, 2011, Radiation oncology.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

P. Jänne, K. O'Byrne, T. Mok, 2014, The Lancet. Oncology.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

J. Pignon, B. Milleron, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact

M. Denis, J. Bennouna, E. Pons-Tostivint, 2021, Cells.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer

P. Laurent-Puig, H. Blons, J. Launay, 2019, EBioMedicine.

The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer

P. Gourraud, C. Brochier, A. Jarry, 2021, Cancers.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

J. Nemunaitis, C. Verschraegen, A. von Heydebreck, 2019, JAMA oncology.

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

J. Lunceford, S. Jalal, S. Piha-Paul, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study

J. Douillard, G. Milano, P. Follana, 2012, Chemotherapy.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

W. Scheithauer, E. Van Cutsem, M. Moore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

T. Conroy, C. Borel, G. Deplanque, 2019, JAMA oncology.

Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.

J. Bennouna, S. M. Moreno Vera, 2016, Future oncology.

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

A. Monnier, J. Douillard, X. Sun, 2001, British Journal of Cancer.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

N. Rioux-Leclercq, F. Beuvon, A. Lièvre, 2022, Clinics and research in hepatology and gastroenterology.

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

C. Tournigand, C. Borg, T. Mazard, 2020, Journal for ImmunoTherapy of Cancer.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

P. Laurent-Puig, F. Penault-Llorca, C. Borg, 2019, European journal of cancer.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

R. Govindan, G. Fasola, P. Postmus, 2018, Cancer.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

M. Denis, J. Bennouna, D. Coupez, 2020, Expert review of anticancer therapy.

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

J. Douillard, D. Valmori, M. Ayyoub, 2012, Cancer research.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

T. Conroy, M. Ychou, O. Bouché, 2017, Oncology.

Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer

J. Douillard, J. Bennouna, 2002, International Journal of Clinical Oncology.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

G. Scagliotti, F. Shepherd, S. Novello, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Tae-You Kim, I. Láng, J. Douillard, 2011, Investigational New Drugs.

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Christophe Letellier, Amylou C. Dueck, Ethan Basch, 2019, JAMA.

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

C. Letellier, O. Molinier, P. Solal-Céligny, 2017, Journal of the National Cancer Institute.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.

J. Douillard, S. Hiret, J. Bennouna, 2011, Lung cancer.

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

E. Van Cutsem, D. Richel, J. Furuse, 2011, The Lancet. Oncology.

Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies

D. Planchard, J. Schellens, W. Miller, 2019, Clinical Trials.

Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

J. Emile, F. Ghiringhelli, D. Vernerey, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

V. Brusic, J. Kirkwood, H. Zarour, 2002, Cancer research.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

D. Planchard, J. Schellens, W. Miller, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).

G. Salles, D. Berton‐Rigaud, J. Rey, 2015 .

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

B. Besse, K. Bouledrak, V. Westeel, 2022, ESMO open.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

M. Rimbert, H. Bruzzoni-Giovanelli, F. Calvo, 2010, Cancer Immunology, Immunotherapy.

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

J. Douillard, M. Hebbar, J. Seitz, 2005, British Journal of Cancer.

Cells 2 T Cell Response to Colon Carcinoma δ 9V γ V

Marc Bonneville, Francine Jotereau, Jaafar Bennouna, 2013 .

Cells 2 T Cell Response to Colon Carcinoma d 9V g V

M. Bonneville, J. Mosnier, A. Moreau-Aubry, 2005 .

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

T. Conroy, P. Laurent-Puig, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2017, Seminars in oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

A. Santoro, J. von Pawel, L. Paz-Ares, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

S. Barry, Michael Thomas, N. Rizvi, 2021 .

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Sung-Bae Kim, M. Shah, F. Lordick, 2019, Journal of Clinical Oncology.

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial

T. Conroy, A. Lièvre, M. Ducreux, 2016, Cancer Chemotherapy and Pharmacology.

Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

F. Grossi, L. Havel, J. Bennouna, 2016, Current medical research and opinion.

433P Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial

C. Borg, A. Bertaut, Jean-David Fumet, 2021, Annals of Oncology.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

R. Ramlau, M. Krzakowski, A. Santoro, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic score for synchronous metastatic rectal cancer: A real-world study.

A. Lièvre, R. Guimbaud, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

R. Greil, S. Kubicka, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook

J. Ajani, Jian Zhang, Bo Zhang, 2021, Annals of translational medicine.

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

T. Conroy, C. Mariette, G. Piessen, 2019, European journal of cancer.

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

J. Douillard, P. Kosmidis, M. O'Brien, 2006, British Journal of Cancer.

Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer.

E. Basch, B. Detournay, E. Voog, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.

E. Raymond, M. Campone, J. Armand, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

J. Douillard, H. Naman, P. Piedbois, 2007, British Journal of Cancer.

Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.

J. Nemunaitis, C. Verschraegen, A. Dowlati, 2018 .

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

R. Salazar, J. Tabernero, B. Melichar, 2011, British Journal of Cancer.

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

C. Borg, O. Bouché, F. Ghiringhelli, 2015 .

Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells

M. Lotze, A. Amoscato, J. Bennouna, 2006, International journal of urology : official journal of the Japanese Urological Association.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

N. Isambert, Jean Fan, J. Delord, 2018, Investigational New Drugs.

A fatal case associated with Catabacter hongkongensis bacteremia in lung cancer patient: A case report

S. Corvec, P. Bémer, J. Bennouna, 2022, IDCases.

Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results.

C. Letellier, E. Basch, O. Molinier, 2018 .

Radiobiological and dosimetric impact of RayStation pencil beam and Monte Carlo algorithms on intensity‐modulated proton therapy breast cancer plans

S. Rana, J. Bennouna, E. J. J. Samuel, 2019, Journal of applied clinical medical physics.

OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC

C. Redfern, K. Kelly, C. Verschraegen, 2017 .

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.

Jaafar Bennouna, Jean-Yves Douillard, J. Douillard, 2013, Lung cancer.

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.

Ying Cheng, R. Kaiser, J. von Pawel, 2015, Lung cancer.

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction

A. Ravaud, P. Fumoleau, F. Saliba, 2013, Investigational New Drugs.

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability.

C. Tournigand, A. Duval, C. Prunier, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology

L. Sequist, Wenbo Tang, L. Paz-Ares, 2017 .

DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

M. Reck, V. Gorbounova, F. Grossi, 2012 .

The Role of UFT in Metastatic Colorectal Cancer

J. Douillard, J. Bennouna, M. Saunders, 2009, Oncology.

Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules

J. Delord, J. Bennouna, P. Ferré, 2012, Clinical Pharmacokinetics.

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

J. Cortés, J. Vermorken, E. Calvo, 2012, Cancer Chemotherapy and Pharmacology.

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

C. Lepage, V. Boige, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.

J. Douillard, L. Campion, S. Hiret, 2016, Clinical colorectal cancer.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

L. Sequist, K. O'Byrne, T. Mok, 2017 .

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2021 .

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial.

C. Letellier, O. Molinier, P. Solal-Céligny, 2016 .

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.

E. Lemarié, B. Milleron, A. Monnier, 2000, European journal of cancer.

O-0026 Significant Relationship Between CA19-9 Kinetics and Overall Survival (OS) from a Phase 3 Trial in Advanced Pancreatic Cancer (APC).

D. Richel, H. Wasan, A. Ricart, 2012 .

Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (M

A. Rossi, C. Gridelli, C. Langer, 2011, Clinical lung cancer.

Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.

C. Borg, Jean-David Fumet, F. Ghiringhelli, 2020 .

Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrhea management: A phase I multicenter trial.

J. Tabernero, B. Melichar, J. Bridgewater, 2006, Journal of Clinical Oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results

E. Tan, J. Douillard, P. Kosmidis, 2004 .

Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016 .

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10min infusion every 3 weeks in patients with advanced solid tumours

E. Raymond, M. Campone, J. Armand, 2002 .

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

S. Olschwang, V. Boige, O. Bouché, 2016 .

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Cristina Santos, H. Hurwitz, J. Bendell, 2017 .

[Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer].

S. Hiret, J. Bennouna, H. Sénellart, 2014, Bulletin du cancer.

6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704

R. Ramlau, P. Zatloukal, N. Leighl, 2007 .

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

R. Boidot, C. Borg, A. Bertaut, 2023, Nature Medicine.

3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial

J. Nemunaitis, A. Heydebreck, J. Gulley, 2015 .

Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer.

J. Douillard, B. Buecher, M. Mahé, 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.

J. Pignon, B. Milleron, J. Soria, 2015 .

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

N. Girard, E. Felip, Dong-Wan Kim, 2021 .

Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression

C. Redfern, K. Kelly, A. Heydebreck, 2016 .

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib

F. Vallette, D. Decaudin, A. Savina, 2017, Molecular Cancer Therapeutics.

Non-small-cell lung cancer: should histology guide chemotherapy treatment?

J. Douillard, J. Bennouna, H. Sénellart, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].

D. Moro-Sibilot, F. Scotté, M. Wislez, 2014, Bulletin du cancer.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

R. Greil, S. Kubicka, M. Makrutzki, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

P. Laurent-Puig, M. Ychou, O. Bouché, 2011 .

Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT)

M. Ducreux, B. Asselain, T. André, 2017, Clinical colorectal cancer.

Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study

D. Planchard, B. Besse, P. Garrido, 2016 .

A Phase II Trial of Raltitrexed (Tomudex®) in Advanced Pancreatic and Biliary Carcinoma

H. Bourgeois, J. Douillard, M. Hebbar, 2005, Oncology.

PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy

C. Volteau, Y. Péréon, C. Pétorin, 2023, Trials.

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

J. Douillard, D. Valmori, M. Ayyoub, 2012, Cancer research.

Vinflunine: A New Microtubule Inhibitor Agent

M. Campone, L. Nguyen, J. Delord, 2008, Clinical Cancer Research.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Jie Yang, L. Sequist, K. O'Byrne, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].

A. Jarry, N. Gervois, C. Bossard, 2018, Bulletin du cancer.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

H. Naman, P. Piedbois, J. Delord, 2007, British Journal of Cancer.

LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Ying Cheng, D. Carbone, L. Paz-Ares, 2020 .

Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.

M. Denis, S. Hiret, J. Bennouna, 2023, Clinical lung cancer.

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.

E. Felip, R. Caparica, M. Garassino, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. DeMichele, B. Melichar, P. Zatloukal, 2015, The Lancet. Oncology.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2023, European journal of cancer.

477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

T. Conroy, G. Deplanque, C. Borg, 2017 .

Treatment of gastric adenocarcinoma: A rapidly evolving landscape.

J. Bennouna, E. Samalin, A. Zaanan, 2023, European journal of cancer.